The Yuvaan Tiwari Foundation invested in KiraGen Bio to support the company's work on durable cell-therapy approaches for brain cancers.
Parvati and Satya Tiwari established the Foundation in memory of their son Yuvaan, who was diagnosed with diffuse midline glioma. The organization supports research and families affected by DMG, DIPG, and related pediatric brain cancers.
The investment connects the Foundation's disease-focused mission with KiraGen's work on cell therapies designed to remain functional under suppressive tumor pressure.